LONDON (Alliance News) - Sareum Holdings PLC on Tuesday said the US Patent and Trademark Office has granted a further patent for Sareum's Kinase inhibitors.
Sareum said the granting of the patent means it has extended its approved patent protection in the US for key elements of the SKIL drug discovery platform, adding to similar patent protections it has secured in Japan and China and which it expects to secure in Europe and other markets imminently.
The patent relates to compounds which inhibit or modulate the activity of kinase enzymes.
"This further grant of patent coverage for Sareum in the USA continues the strengthening of our patent portfolio, and enhances our negotiating position with potential licensing and collaboration partners," said Sareum Chief Scientific Officer John Reader.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Sareum (SAR)